Conditional Survival and Annual Hazard Estimates of Classical Hodgkin Lymphoma

References

• CazzolaM. Introduction to a review series: the 2016 revision of the WHO classification of tumors of hematopoietic and lymphoid tissues. Blood. 2016;127(20):2361–2364. doi:10.1182/blood-2016-03-65737927069255
   PubMed Web of Science ®Google Scholar
• TorokJA, WuY, ChinoJ, et al. Chemotherapy or combined modality therapy for early-stage hodgkin lymphoma. Anticancer Res. 2018;38(5):2875–2881.29715111
   PubMed Web of Science ®Google Scholar
• EichHT, DiehlV, GörgenH, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: final analysis of the german hodgkin study group HD11 trial. J Clin Oncol. 2010;28(27):4199–4206. doi:10.1200/JCO.2010.29.801820713848
   PubMed Web of Science ®Google Scholar
• EngertA, SchillerP, JostingA, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin’s lymphoma: results of the HD8 trial of the German Hodgkin’s lymph. J Clin Oncol. 2003;21(19):3601–3608. doi:10.1200/JCO.2003.03.02312913100
   PubMed Web of Science ®Google Scholar
• NaghaviM, AbajobirAA, AbbafatiC, et al. Global, regional, and national age-sex specifc mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1151–1210.28919116
   PubMed Web of Science ®Google Scholar
• LiuW, JiX, SongY, et al. Improving survival of 3760 patients with lymphoma: experience of an academic center over two decades. Cancer Med. 2020;9(11):3765–3774. doi:10.1002/cam4.303732281275
   PubMed Web of Science ®Google Scholar
• XieY, WangX, LengX, et al. High-dose chemotherapy followed by autologous stem cell transplantation for patients with refractory/relapsed classical Hodgkin lymphoma: a single center experience from China. Ann Hematol. 2020;99(3):549–555. doi:10.1007/s00277-019-03812-w31980860
   PubMed Web of Science ®Google Scholar
• ZaborEC, GonenM, ChapmanPB, PanageasKS. Dynamic prognostication using conditional survival estimates. Cancer. 2013;119(20):3589–3592. doi:10.1002/cncr.2827323913639
   PubMed Web of Science ®Google Scholar
• AndersonC, SmithermanAB, NicholsHB. Conditional relative survival among long-term survivors of adolescent and young adult cancers. Cancer. 2018;124(14):3037–3043. doi:10.1002/cncr.3152929742278
   PubMed Web of Science ®Google Scholar
• WangSJ, EmeryR, FullerCD, KimJS, SittigDF, ThomasCR. Conditional survival in gastric cancer: a SEER database analysis. Gastric Cancer. 2007;10(3):153–158. doi:10.1007/s10120-007-0424-917922092
   PubMed Web of Science ®Google Scholar
• LeeJW, AliB, YooHM, ParkCH, SongKY. Conditional survival analysis in Korean patients with gastric cancer undergoing curative gastrectomy. BMC Cancer. 2015;15(1):1–7. doi:10.1186/s12885-015-2022-225971837
   PubMed Web of Science ®Google Scholar
• HoppeRT, AdvaniRH, AiWZ, et al. Hodgkin lymphoma version 1.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2017;15(5):608–638. doi:10.6004/jnccn.2017.0064
   PubMed Web of Science ®Google Scholar
• KimY, EjazA, SpolveratoG, et al. Conditional survival after surgical resection of gastric cancer: a multi-institutional analysis of the US Gastric Cancer Collaborative. Ann Surg Oncol. 2015;22(2):557–564. doi:10.1245/s10434-014-4116-525287440
   PubMed Web of Science ®Google Scholar
• HapgoodG, ZhengY, SehnLH, et al. Evaluation of the risk of relapse in classical Hodgkin lymphoma at event-free survival time points and survival comparison with the general population in British Columbia. J Clin Oncol. 2016;34(21):2493–2500.27269949
   PubMed Web of Science ®Google Scholar
• HessKR, LevinVA. Getting more out of survival data by using the hazard function. Clin Cancer Res. 2014;20(6):1404–1409.24501392
   PubMed Web of Science ®Google Scholar
• PedersenNT, ChristensenBE. Conditional survival of patients with diffuse large B-cell Lymphoma. Cancer. 2006;106:2165–2170.16586498
   PubMed Web of Science ®Google Scholar
• MaurerMJ, EllinF, SrourL, et al. International assessment of event-free survival at 24 months and subsequent survival in peripheral T-cell lymphoma. J Clin Oncol. 2017;35(36):4019–4026. doi:10.1200/JCO.2017.73.819529072976
   PubMed Web of Science ®Google Scholar
• MaurerMJ, GhesquièresH, JaisJP, et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol. 2014;32(10):1066–1073. doi:10.1200/JCO.2013.51.586624550425
   PubMed Web of Science ®Google Scholar
• WitzigTE, HongF, HaiounC, et al. 24 months in patients with diffuse large B-cell lymphoma. Am J Hematol. 2016;91(2):179–184.26492520
   PubMed Web of Science ®Google Scholar
• WangYG, ZhaoLY, LiuCQ, et al. Clinical characteristics and prognostic factors of primary gastric lymphoma: a retrospective study with 165 cases. Med (United States). 2016;95(31):1–6.
   Google Scholar
• LiuX, WuT, ZhuSY, et al. Risk-dependent conditional survival and failure hazard after radiotherapy for early-stage extranodal natural killer/T-cell Lymphoma. JAMA Netw open. 2019;2(3):e190194. doi:10.1001/jamanetworkopen.2019.019430821826
   PubMed Web of Science ®Google Scholar
• Von TresckowB, PlütschowA, FuchsM, et al. Dose-intensification in early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin study group HD14 trial. J Clin Oncol. 2012;30(9):907–913. doi:10.1200/JCO.2011.38.580722271480
   PubMed Web of Science ®Google Scholar
• CardeP, KarraschM, FortpiedC, et al. Eight cycles of ABVD versus four cycles of BEACOPPescalated plus four cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, high-risk Hodgkin lymphoma: first results of the Phase III EORTC 20012 intergroup trial. J Clin Oncol. 2016;34(17):2028–2036. doi:10.1200/JCO.2015.64.564827114593
   PubMed Web of Science ®Google Scholar
• VivianiS, ZinzaniPL, RambaldiA, et al. ABVD versus BEACOPP for Hodgkin’s lymphoma when high-dose salvage is planned. New Eng J Med. 2011;365:203–212.21774708
   PubMed Web of Science ®Google Scholar